Recent Advances in Gastrointestinal Disease: Insights into Drug Delivery and Cellular and Molecular Mechanisms for Therapy

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: 30 September 2025 | Viewed by 470

Special Issue Editors


E-Mail Website
Guest Editor
National Institute of Gastroenterology S. De Bellis, IRCCS Research Hospital, Via Turi 27, 70013 Castellana Grotte, Italy
Interests: microRNA; gastrointestinal cancer; inflammatory bowel disease; molecular biomarkers; molecular therapy

Special Issue Information

Dear Colleagues,

Gastrointestinal (GI) diseases include a wide range of conditions affecting the digestive tract, including cancer, chronic inflammatory and immune diseases, and functional and metabolic disorders. Recent advancements in cellular and molecular biology have provided critical insights into the underlying pathophysiology of these disorders, facilitating the development of more precise and effective therapeutic strategies that minimize damage to healthy cells and significantly reduce side effects. The substantial progress in genomic technologies and multi-omics approaches has allowed the identification of new potential targets involved in dysfunctional signaling pathways and the tailoring of innovative and specific therapy like novel small-molecule inhibitors, RNA-based molecules, monoclonal antibodies, immunotherapy and immune checkpoint inhibitors. In addition, innovative drug delivery platforms and modeling techniques are enhancing our knowledge of drug efficacy and cellular heterogeneity, providing deeper insights into the pharmacodynamic, pharmacokinetic, immunogenic and toxicological properties of drugs.

This Special Issue invites researchers to submit original research articles or reviews exploring drug delivery systems. Promising strategies for drug delivery to improve compound bioavailability and stability, cell physiological responses and on-target drug distribution are of broad interest.

Submissions focused on, but not limited to, novel therapeutic strategies to enhance treatment efficacy in GI diseases, and combination and multi-targeted therapies are all welcome.

Dr. Amilcare Barca
Dr. Emanuele Piccinno
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastrointestinal disease
  • drug delivery
  • molecular therapy
  • biological therapy
  • target therapy
  • molecular target
  • biomarkers
  • GI epithelial cells

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

25 pages, 3433 KB  
Article
Exploring miRNA Research in Colorectal Cancer: Insights from a Bibliometric Analysis
by Emanuele Piccinno, Michelangelo Aloisio, Viviana Scalavino, Francesco Russo, Gianluigi Giannelli, Davide Guido and Grazia Serino
Pharmaceutics 2025, 17(8), 1084; https://doi.org/10.3390/pharmaceutics17081084 - 21 Aug 2025
Viewed by 301
Abstract
Background/Objectives: Despite advances in diagnosis and treatment, colorectal cancer (CRC) remains one of the most prevalent and challenging malignancies worldwide. The dysregulation of microRNAs (miRNAs) has emerged as a critical factor in CRC onset, progression, and therapeutic resistance. This study aims to [...] Read more.
Background/Objectives: Despite advances in diagnosis and treatment, colorectal cancer (CRC) remains one of the most prevalent and challenging malignancies worldwide. The dysregulation of microRNAs (miRNAs) has emerged as a critical factor in CRC onset, progression, and therapeutic resistance. This study aims to provide an overview of global research trends on miRNAs in CRC, (i) identifying the most studied miRNAs, (ii) exploring under-investigated areas, and (iii) highlighting emerging themes and potential future directions. Methods: To assess the evolution of the global miRNA–CRC research trends, we conducted a bibliometric analysis of 828 CRC–miRNA-focused articles published between 2008 and 2024, sourced from the Scopus database. Bibliometric mapping was performed using the R/Bibliometrix package and by leveraging a customized Python-based pipeline, which is useful for extracting and validating miRNA identifiers (miRNA IDs) based on the miRBase database. This miRNA ID-related approach enabled us to systematically identify the most frequently studied miRNAs over time while highlighting underexplored miRNA. Results: The analysis revealed a substantial and accelerating publication growth rate, delineating three major phases in CRC–miRNA research. China emerged as the leading contributor in terms of the publication volume. miR-21, miR-34a, and miR-195-5p were among the most frequently studied miRNAs, underscoring their relevance to CRC biology and therapy. Keyword and citation analyses identified key thematic areas, such as cell proliferation, epithelial–mesenchymal transition, and chemoresistance, especially to oxaliplatin and 5-fluorouracil. Emerging research frontiers included ferroptosis, ceRNA networks, and exosome-mediated miRNA transport. An analysis of the collaborations indicated strong intra-national collaborations, with room for expanding international research networks. Conclusions: This study provides an in-depth bibliometric landscape of the CRC-related miRNA research by highlighting influential studies and journals while identifying gaps and underexplored topics. These insights offer valuable guidance for future translational and clinical research on this topic. Full article
Show Figures

Figure 1

Back to TopTop